BRPI0715845A2 - Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão - Google Patents

Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão

Info

Publication number
BRPI0715845A2
BRPI0715845A2 BRPI0715845-9A2A BRPI0715845A BRPI0715845A2 BR PI0715845 A2 BRPI0715845 A2 BR PI0715845A2 BR PI0715845 A BRPI0715845 A BR PI0715845A BR PI0715845 A2 BRPI0715845 A2 BR PI0715845A2
Authority
BR
Brazil
Prior art keywords
lung cancer
pharmaceutical composition
growth inhibition
cancer treatment
invasion
Prior art date
Application number
BRPI0715845-9A2A
Other languages
English (en)
Inventor
Hyo Jeong Hong
Jun-Whoi Lee
Jin Man Kim
Yeon Sung Son
Eung Suck Lee
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Publication of BRPI0715845A2 publication Critical patent/BRPI0715845A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0715845-9A2A 2006-08-23 2007-08-23 Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão BRPI0715845A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20060079969 2006-08-23
KR1020070084869A KR100932698B1 (ko) 2006-08-23 2007-08-23 폐암의 치료용 약제학적 조성물 및 이를 이용한 폐암의성장, 전이 억제 및 치료방법
PCT/KR2007/004045 WO2008023946A1 (en) 2006-08-23 2007-08-23 A pharmaceutical composition for treating lung cancer, a method for inhibiting growth or invasion of lung cancer and a method for treating lung cancer

Publications (1)

Publication Number Publication Date
BRPI0715845A2 true BRPI0715845A2 (pt) 2014-11-11

Family

ID=39385312

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0715845-9A2A BRPI0715845A2 (pt) 2006-08-23 2007-08-23 Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
BRPI0715844-0A BRPI0715844A2 (pt) 2006-08-23 2007-08-23 Composição farmacêutica para tratamento do colangiocarcinoma, método de inibição do crescimento ou invasão do colangiocarcinoma e método de tratamento do colangiocarcinoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0715844-0A BRPI0715844A2 (pt) 2006-08-23 2007-08-23 Composição farmacêutica para tratamento do colangiocarcinoma, método de inibição do crescimento ou invasão do colangiocarcinoma e método de tratamento do colangiocarcinoma

Country Status (10)

Country Link
US (1) US8153122B2 (pt)
EP (2) EP2054083B1 (pt)
JP (3) JP2010501548A (pt)
KR (2) KR100932698B1 (pt)
CN (2) CN101605560B (pt)
AU (2) AU2007288620B2 (pt)
BR (2) BRPI0715845A2 (pt)
CA (2) CA2661669C (pt)
MX (2) MX2009002065A (pt)
WO (2) WO2008023947A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605560B (zh) * 2006-08-23 2013-06-26 韩国生命工学研究院 治疗胆管癌的药物组合物
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
CA2718774A1 (en) * 2008-03-17 2009-12-17 Regenerx Biopharmaceuticals, Inc. Improved beta thymosin fragments
RU2377004C1 (ru) * 2008-07-04 2009-12-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения нерезектабельного рака желчных путей
KR20100060351A (ko) 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
JP5716257B2 (ja) * 2009-02-06 2015-05-13 国立大学法人 熊本大学 胆管癌特異的糖鎖エピトープを認識するモノクローナル抗体
KR101271964B1 (ko) * 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
JP2014521958A (ja) * 2011-07-28 2014-08-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法
CN104936984B (zh) 2012-11-16 2018-09-14 江原大学校产学协力团 特异性结合人和小鼠l1cam的抗体及其用途
CA2924543A1 (en) * 2013-09-18 2015-03-26 Memorial Sloan-Kettering Cancer Center Inhibiting cancer metastasis
SG10201806064XA (en) * 2014-08-27 2018-08-30 Peptimed Inc Anti-tumor compositions and methods
CN104894259A (zh) * 2015-06-01 2015-09-09 北京泱深生物信息技术有限公司 Tex19基因在胆管癌诊断和治疗中的应用
KR101892908B1 (ko) 2015-11-02 2018-08-29 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물
US11260062B2 (en) 2015-11-02 2022-03-01 Ajou University Industry-Academic Cooperation Foundation Pharmaceutical composition for treatment of lung cancer comprising glucocorticoid-based compound
KR20230170142A (ko) * 2016-08-02 2023-12-18 메모리얼 슬로안 케터링 캔서 센터 전이성 암의 치료 및 전이성 질환에 대한 모델 시스템
KR20180079232A (ko) * 2016-12-30 2018-07-10 강원대학교산학협력단 L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP3638299A4 (en) * 2017-06-15 2021-03-31 Memorial Sloan-Kettering Cancer Center ANTI-L1-CAM ANTIBODIES AND THEIR USES
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
SG10201902000YA (en) 2019-03-06 2020-10-29 Nat Univ Singapore Isthmin 1 for treatment of lung inflammation
GB201913123D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN111053774B (zh) * 2019-12-20 2022-10-11 厦门大学 盐酸他克林在制备治疗胆管癌的药物中的应用
CN112239505B (zh) * 2020-10-13 2022-05-20 上海良润生物医药科技有限公司 重组抗cd171八价抗体及神经来源外泌体的捕获方法
EP4414388A4 (en) * 2021-11-03 2025-10-29 Curon Biopharmaceutical Shanghai Co Ltd NEW ANTI-L1CAM ANTIBODY
CN114657129B (zh) * 2022-04-11 2023-12-01 中山大学孙逸仙纪念医院 一种胆管癌淋巴结转移动物模型及其构建方法
CN114917348B (zh) * 2022-06-21 2023-08-04 四川大学华西医院 神经粘附因子在制备抑制和标记肝癌细胞转移的试剂中的应用
WO2024204325A1 (ja) * 2023-03-28 2024-10-03 東レ株式会社 細胞膜タンパク質を検出する方法
CN117379550A (zh) * 2023-08-22 2024-01-12 上海懿贝瑞生物医药科技有限公司 Spanxb1基因抑制剂及其制备方法和用途
CN119096936A (zh) * 2024-08-28 2024-12-10 南方医科大学第三附属医院（广东省骨科研究院） 一种胆管癌足垫腘窝淋巴结自发转移动物模型的构建方法
CN119492873A (zh) * 2024-10-16 2025-02-21 吉林大学 基于生物偶联策略的细胞表面待测细胞因子富集系统及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872225A (en) * 1992-06-26 1999-02-16 Case Western Reserve University Method for characterizing the nucleotide sequence of L1CAM and the nucleotide sequence characterized thereby
ATE377192T1 (de) 2000-07-10 2007-11-15 Deutsches Krebsforsch Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
US20040082847A1 (en) * 2002-10-23 2004-04-29 Mcdermott Kathleen B. System and methods for identifying brain regions supporting language
WO2004037198A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Antibody-mediated induction of tumor cell death
EP1671645A4 (en) * 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
EP1623995A1 (en) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
CN101605560B (zh) * 2006-08-23 2013-06-26 韩国生命工学研究院 治疗胆管癌的药物组合物

Also Published As

Publication number Publication date
AU2007288620A1 (en) 2008-02-28
KR20080018149A (ko) 2008-02-27
CA2661669A1 (en) 2008-02-28
US20100196350A1 (en) 2010-08-05
CN101605560A (zh) 2009-12-16
KR20080018150A (ko) 2008-02-27
EP2054083B1 (en) 2013-11-27
JP2010501549A (ja) 2010-01-21
EP2051733A1 (en) 2009-04-29
JP5923233B2 (ja) 2016-05-24
AU2007288619A1 (en) 2008-02-28
CN101528258A (zh) 2009-09-09
MX2009002064A (es) 2009-06-30
EP2054083A4 (en) 2010-03-24
CN101605560B (zh) 2013-06-26
BRPI0715844A2 (pt) 2013-11-26
JP2010501548A (ja) 2010-01-21
KR100931976B1 (ko) 2009-12-15
US8153122B2 (en) 2012-04-10
KR100932698B1 (ko) 2009-12-21
JP2015007045A (ja) 2015-01-15
AU2007288620B2 (en) 2012-08-30
WO2008023947A1 (en) 2008-02-28
CA2661665A1 (en) 2008-02-28
MX2009002065A (es) 2009-06-30
WO2008023946A1 (en) 2008-02-28
CA2661669C (en) 2017-02-14
EP2054083A1 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
BRPI0813001A2 (pt) composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica
BRPI1007379A2 (pt) composições e métodos para o tratamento ou a prevenção de infecções orais por e. coli
ZA200707638B (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
HUE041764T2 (hu) Kollagén-mediálta betegségek kezelésére alkalmas kompozíciók
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
IL287975A (en) Skin care system
BRPI0811849A2 (pt) Composto, composição farmacêutica, e, métodos para preparar o compost e para tratar doenças ou condições mediadas por ccr1
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
BRPI0717741A2 (pt) Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]